Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This report presents a rare case where a patient with chronic urticaria developed alopecia areata during azathioprine therapy, accompanied by bone marrow suppression; these effects resolved after stopping the medication, suggesting a possible link between azathioprine and autoimmune activation despite its intended immunosuppressive use.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This case series observed that 57% of pediatric patients with alopecia areata experienced significant hair regrowth with methotrexate treatment, which was generally safe, although some results were inconclusive due to follow-up issues.

This study found that acetyl zingerone methyl ether (MAZ) in hair dyes and haircare products may reduce oxidative damage, improve hair condition, and enhance the longevity and quality of dyed hair color.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

This study supports the traditional use of T. procumbens for diabetes treatment, showing improvements in body weight and glucose tolerance with no toxicity signs in normal rats.

This review found no evidence supporting the efficacy of methotrexate for inducing remission in active ulcerative colitis compared to placebo or active comparators.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This study used a zebrafish model and advanced mass spectrometry to identify 11 metabolites of epristeride, revealing significant effects on purine metabolism and aromatic amino acid biosynthesis, which may aid in developing anti-doping detection methods.

This review discusses the diverse pharmacological activities of T. procumbens, such as hypotensive and hair growth-promoting effects, but reports no new clinical findings.

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

In this study, researchers found that combining cryotherapy with triamcinolone injections is equally effective as triamcinolone alone for treating patchy alopecia areata on the scalp and face, with no significant difference in outcomes between the two methods.

This article discusses the importance of raising awareness about specific adverse drug reactions, methods of prevention, and the significance of reporting them to the FDA's MedWatch program, but reports no new clinical results.

This study observed that excimer light therapy, intralesional triamcinolone, and topical 5% minoxidil all had differing levels of effectiveness in treating alopecia areata, with variable results noted among treatments.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.

This study is the first to report that apremilast may be effective in treating refractory lichen planopilaris and frontal fibrosing alopecia, though some patients experienced adverse effects leading to discontinuation.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This observational study reports that a TRASER device using specific wavelengths for vascular and follicular targets showed both clinical responses and histological changes, suggesting its potential as an effective vascular and hair removal tool.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

In a pilot study examining potential treatments for androgenic alopecia, researchers reported that over four months, topical cetirizine 1% improved hair length but not other measures, while diclofenac 3% showed no significant effects, unlike minoxidil, which showed significant improvement across all measured variables.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

This article reviews new drug combinations and unique agents for rheumatoid arthritis but reports no clinical results; the authors highlight several promising compounds awaiting approval.